藥明生物(02269.HK)與OncoC4建立獨家CDMO合作夥伴關係
藥明生物(02269.HK)宣布,與臨床階段生物製藥公司OncoC4就其全部研發管線建立獨家CDMO合作夥伴關係。OncoC4的研發管線包括新一代CTLA-4抗體ONC-392,目前該抗體正在美國和中國進行I期臨床試驗。
根據協議,藥明生物將作為獨家CDMO合作夥伴提供一體化研發和生產服務,滿足OncoC4的生物藥從早期研究、臨床前至商業化階段的需求。OncoC4將充分利用藥明生物在細胞株、製劑等工藝開發,以及生物藥原液和製劑生產領域的技術能力和經驗,加速產品開發進程。
OncoC4並將進一步與藥明生物擴大合作至雙特異性抗體領域。根據協議,OncoC4獲得授權使用WuXiBody技術平台發現和開發雙抗藥物;除首付款外,藥明生物還將獲得WuXiBody平台雙抗藥物的開發和商業化里程碑付款,以及產品上市後的淨銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.